Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Nanobody-Based Diagnostics Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
The nanobody-based diagnostics market size has demonstrated rapid expansion in recent years. Projections indicate it will grow from $1.13 billion in 2025 to $1.27 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.7%. The market’s historical growth is attributable to several factors, including advancements in antibody engineering technologies, an escalating prevalence of infectious diseases, a rise in cancer diagnostics demand, increased research funding in immunodiagnostics, and the proliferation of rapid diagnostic testing platforms.
The nanobody-based diagnostics market is projected to experience swift expansion over the coming years. Its valuation is anticipated to reach $2.07 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.0%. Several factors are contributing to this growth during the forecast period, including an escalating need for precision diagnostics, greater integration of AI-driven assay analysis instruments, the surging uptake of microfluidic biosensor technologies, the broadening scope of decentralized diagnostic testing, and a heightened emphasis on biomarkers for early disease detection. Key trends observed over the forecast duration encompass the increasing acceptance of lateral flow nanobody assays, a heightened requirement for high-affinity single-domain antibody reagents, the expanding incorporation of nanobodies into point-of-care diagnostic solutions, the proliferation of platforms for multiplexed biomarker detection, and the growing application of nanobody-centric imaging in monitoring diseases.
Get A Free Sample Report With In-Depth Market Insights:
Nanobody-Based Diagnostics Market Growth Momentum: What Factors Are Shaping Demand?
The increasing incidence of infectious diseases is anticipated to fuel the expansion of the nanobody based diagnostics market in the future. These diseases are defined as conditions resulting from harmful microorganisms like bacteria, viruses, fungi, or parasites, capable of spreading between individuals or via contaminated surroundings. The rise in infectious disease prevalence is attributed to increased human interaction, which facilitates pathogen transmission within populations. Nanobody-based diagnostic tools offer quick, highly specific, and sensitive identification of infectious agents, allowing for prompt diagnosis and intervention. This, in turn, helps manage the propagation of these diseases and enhances patient recovery. For example, in March 2024, the Centers for Disease Control and Prevention, a US-based government agency, reported that tuberculosis cases climbed from 8,320 in 2022 to 9,615 in 2023, representing an increase of 1,295 cases. Consequently, the growing occurrence of infectious diseases is a key factor driving the nanobody based diagnostics market. The escalating healthcare investments are projected to stimulate the expansion of the nanobody based diagnostics market moving forward. Healthcare investments involve the channeling of funds by governments, entities, and medical providers to upgrade medical infrastructure, services, technology, and overall healthcare provision. These investments are growing due to a heightened demand for sophisticated medical services and modern technologies aimed at enhancing patient care and health outcomes. Such funding fosters the advancement and adoption of nanobody based diagnostics by financing cutting-edge research, upgrading laboratory facilities, and empowering healthcare providers to deploy advanced diagnostic tools for more precise and prompt disease identification. For instance, in January 2026, the Centers for Medicare & Medicaid Services, a US-based government agency, reported that in 2024, Medicare spending saw a 7.8% rise, reaching $1,118.0 billion and constituting 21% of total national health expenditures (NHE), concurrently, Medicaid spending increased by 6.6% to $931.7 billion, making up 18% of total NHE. Thus, the increase in healthcare investments is propelling the growth of the nanobody based diagnostics market.
Nanobody-Based Diagnostics Market Segment Outlook: Which Categories Are Growing Fastest?
The nanobody-based diagnostics market covered in this report is segmented –
1) By Technology: Immunoassays, Molecular Diagnostics, Biosensor-Based Detection, Fluorescence And Imaging Diagnostics
2) By Product Type: Reagents, Kits, Instruments, Other Product Types
3) By Application: Infectious Diseases, Oncology, Autoimmune Disorders, Cardiovascular Diseases, Other Applications
4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Research Institutes, Other End Users
Subsegments:
1) By Immunoassays: Enzyme Linked Immunosorbent Assay, Western Blotting, Lateral Flow Assay, Radioimmunoassay
2) By Molecular Diagnostics: Polymerase Chain Reaction Based Assays, Nucleic Acid Hybridization, Next Generation Sequencing, Isothermal Amplification Techniques
3) By Biosensor Based Detection: Electrochemical Biosensors, Optical Biosensors, Piezoelectric Biosensors, Microfluidic Biosensors
4) By Fluorescence and Imaging Diagnostics: Fluorescence Microscopy, Flow Cytometry, Fluorescence In Situ Hybridization, Molecular Imaging Techniques
Nanobody-Based Diagnostics Market Trends Redefining Industry Growth
Major companies operating in the nanobody-based diagnostics market are prioritizing the development of innovative solutions, including advanced nanobody platforms, to enhance the accuracy and speed of disease detection. These sophisticated nanobody platforms employ small, single-domain antibodies known for their high specificity and stability, which enables more rapid tissue penetration, improved targeting of disease biomarkers, and superior diagnostic and therapeutic effectiveness compared to conventional antibodies. For example, in September 2025, Cyclotek Pty Ltd, an Australia-based radiopharmaceutical company, was awarded a CRC-P Round 16 grant by the Australian Government to advance a nanobody-based theranostic platform for cancer. This project, undertaken in collaboration with the University of Melbourne, Revela Bio Inc., and several local SMEs, concentrates on creating targeted diagnostics and therapeutics that leverage nanobodies against the Fibroblast Activation Protein (FAP), a biomarker highly expressed in aggressive cancers such as lung, pancreatic, and ovarian cancer. Nanobodies merge the precise targeting of antibodies with the pharmacokinetics of small molecules, rendering them highly suitable for both diagnostic imaging and therapeutic applications. The initiative aims to develop advanced radiolabelling chemistry, conduct pre-clinical evaluations, and progress to first-in-human clinical trials, thereby enabling Cyclotek Pty Ltd to scale and commercialize this innovative platform across Australia, New Zealand, and the broader Asia-Pacific region.
Nanobody-Based Diagnostics Market Industry Leaders And Competitive Landscape
Major companies operating in the nanobody-based diagnostics market are Sanofi S.A., Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., PerkinElmer Inc., Bruker Corporation, Bio-Rad Laboratories Inc., GenScript Biotech Corporation, Biocytogen LLC, Sino Biological Inc., Abzena plc, NanoTemper Technologies GmbH, RayBiotech Inc., Proteintech Group Inc., Creative Biolabs Inc., Isogenica Ltd., Beroni Group Limited, Immudex ApS, Cyclotek Pty Ltd, NanoTag Biotechnologies GmbH.
View The Full Nanobody-Based Diagnostics Market Report:
Nanobody-Based Diagnostics Market Regional Analysis And Leading Geography
North America was the largest region in the nanobody-based diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nanobody-based diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
